Send to

Choose Destination
J Med Chem. 2012 Nov 26;55(22):9708-21. doi: 10.1021/jm3009458. Epub 2012 Oct 17.

Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.

Author information

Drug Discovery and Development, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy.


Herein we report on a novel series of multitargeted compounds obtained by linking together galantamine and memantine. The compounds were designed by taking advantage of the crystal structures of acetylcholinesterase (AChE) in complex with galantamine derivatives. Sixteen novel derivatives were synthesized, using spacers of different lengths and chemical composition. The molecules were then tested as inhibitors of AChE and as binders of the N-methyl-d-aspartate (NMDA) receptor (NMDAR). Some of the new compounds were nanomolar inhibitors of AChE and showed micromolar affinities for NMDAR. All compounds were also tested for selectivity toward NMDAR containing the 2B subunit (NR2B). Some of the new derivatives showed a micromolar affinity for NR2B. Finally, selected compounds were tested using a cell-based assay to measure their neuroprotective activity. Three of them showed a remarkable neuroprotective profile, inhibiting the NMDA-induced neurotoxicity at subnanomolar concentrations (e.g., 5, named memagal, IC(50) = 0.28 nM).

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for American Chemical Society Icon for eScholarship, California Digital Library, University of California
Loading ...
Support Center